US Stem Cell Inc (OTCMKTS:USRM) is a stock we pointed to back in early March as a potential runner. We’ve seen about 230% on the upside since that time, and the company continues to frame its narrative with new catalysts. According to the latest announcement out of USRM, the company has developed a strategic alliance with Advanced Stem Cell Rx (ASC), a US-based provider of regenerative medicine programs, including the development of autologous stem cell treatment centers throughout the US.
“Stem cells are critical to our survival and at the core of our regenerative and healing powers. They will play an immense role in redefining the preferred treatment method for the majority of diseases commonly afflicting mankind. We, at ASC, are proud to form a strong alliance with US Stem Cell Inc., one of the oldest and most respected stem cell research and therapy companies in the world,” stated Dr J.S. Landow, Managing Director of ASC.
US Stem Cell Inc (OTCMKTS:USRM) bills itself as a company committed to the development of effective cell technologies to treat a variety of diseases and injuries. By harnessing the body’s own healing potential, we may be able to reverse damaged tissue to normal function.
U.S. Stem Cell’s discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
USRM is focused on regenerative medicine. While most stem cell companies use one particular cell type to treat a variety of diseases, U.S Stem Cell utilizes various cell types to treat different diseases. It is our belief that the unique qualities within the various cell types make them more advantageous to treat a particular disease.
According to company materials, “US Stem Cell, Inc. (formerly Bioheart, Inc.) is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.”
Find out when USRM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, USRM shares have firmed up once again in part in response to news that the company has formed a strategic alliance with ASC.
According to the recent release, ASC is commercializing many of the proprietary treatments developed by USRM and is currently implementing turnkey programs into qualified practices across the U.S.
Apparently, ASC has contracted with practices in over 20 states in the US, and the company utilizes treatments which “employ over 20 years of US Stem Cell’s international research findings and among the world’s elite cellular scientists and other luminaries in the stem cell field.”
Patient selection is critical, with acceptance for treatment based upon patient’s meeting specific criteria and undergoing a consultation with a member of the clinical team.
The chart shows a bit more than 280% piled on for shareholders of the company during the past month. The situation may continue to be worth watching. USRM stock has a history of dramatic rallies. What’s more, the company has witnessed a pop in interest, as transaction volume levels have recently pushed nearly 310% beyond what we have been seeing over the larger time frame. That’s a continuing explosion of recent interest.
While there is a lot of recent interest, one must remain well-grounded. Not everything is easy to love here. For example, USRM has a chunk ($271K) of cash on the books. But that cash level is dwarfed by a mountain of debt (about $3M in total current liabilities).
That said, USRM is pulling in trailing 12-month revenues of $3.1M. In addition, the company is seeing major top line growth, with y/y quarterly revenues growing at 66.6%. This will likely continue to be a very interesting and lively trading story over the near term, and we will look forward to updating it again soon. For continuing coverage on shares of USRM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!